LCB-2151

LCB-2151 (Compound 2), a nucleoside analogue, is an anticancer agent. LCB-2151 disrupts the two primary sources of ATP production (glycolysis and mitochondrial oxidative phosphorylation), reducing the bioenergetic capacity of KRAS-mutated pancreatic cancer cells and inducing ROS formation. LCB-2151 effectively inhibits key enzymes (such as CACT and CPT2) in glycolysis, the TCA cycle and fatty acid β-oxidation. LCB-2151 has significant cytotoxicity and induces cells apoptosis. LCB-2151 can be used for radiation therapy of cancers research[1].

Product Specifications

CAS Number

[2211175-99-2]

UNSPSC

12352100

Target

Apoptosis; Mitochondrial Metabolism; Oxidative Phosphorylation; Reactive Oxygen Species (ROS)

Related Pathways

Apoptosis; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB

Field of Research

Cancer

Smiles

OC[C@@]1(C)C(F)(F)[C@H](N2C(N=C(NC(CC(C)(C)CC[C@@H](SCC3=CC=C(C(F)(F)F)C=C3)CCSCC4=CC=C(C(F)(F)F)C=C4)=O)C=C2)=O)O[C@@H]1CO

Molecular Formula

C37H43F8N3O5S2

Molecular Weight

825.87

References & Citations

[1]Tantawi H, et al. A Nucleoside Analogue Featuring a C3′-Stereogenic All-Carbon Quaternary Center as a Bioenergetic Disruptor of KRAS-Mutated Pancreatic Cancer Cells[J]. ACS Medicinal Chemistry Letters, 2025.